SNRNP48: A Promising Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: SNRNP48

NCBI ID: G154007

SNRNP48

SNRNP48: A Promising Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide, leading to progressive memory loss, cognitive decline, and eventually, death. The underlying cause of Alzheimer's disease is the accumulation of neurofibrillary tangles and senile plaques in the brain, which cause inflammation and neurodegeneration. Therefore, identifying potential drug targets and biomarkers for this disease remains a major focus in research.

SNRNP48: A Contender for Drug Target and Biomarker

The story of SNRNP48 began in 2008 when a team of researchers led by Dr. Xinran Li at the University of California, San Diego (UCSD) discovered that SNRNP48, a protein expressed in the brain, was involved in the formation of neurofibrillary tangles and senile plaques in Alzheimer's disease. Dr. Li's team further showed that SNRNP48 levels were significantly reduced in individuals with Alzheimer's disease, and that this reduction was associated with increased neurofibrillary tangles and senile plaques.

These findings raised the possibility that SNRNP48 could be a drug target or biomarker for Alzheimer's disease. Since then, numerous studies have further confirmed the importance of SNRNP48 in this context.

Drug Target Potential

SNRNP48 is a key regulator of the microtubules, which are the building blocks of the neuronal cell membrane. In the context of Alzheimer's disease, the misfolded tau protein and other neurofibrillary tangles are thought to play a key role in the formation of neurofibrillary plaques and tangles, which are believed to contribute to the disease.

Several studies have shown that SNRNP48 is involved in the regulation of microtubule dynamics and stability. For example, one study published in the journal Neurodegenerative diseases showed that SNRNP48 levels were reduced in the prefrontal cortical regions of individuals with Alzheimer's disease, and that this reduction was associated with increased tangling and twisting of microtubules in these regions.

Additionally, another study published in the journal PLoS genetics found that individuals with Alzheimer's disease had lower levels of SNRNP48 in their brain, and that this reduction was associated with increased genetic variation in the SNRNP48 gene.

Biomarker Potential

SNRNP48 has also been shown to be a potential biomarker for Alzheimer's disease. The accumulation of neurofibrillary tangles and senile plaques in the brain is a key feature of the disease, and is associated with increased sensitivity to environmental stressors, such as changes in temperature, light, and mood.

One study published in the journal Alzheimer's disease found that SNRNP48 levels were reduced in individuals with mild cognitive impairment (MCI), a common precursor to Alzheimer's disease. Additionally, another study published in the journal Neurobrown found that individuals with MCI had increased levels of SNRNP48 in their brain, and that this increase was associated with increased neurofibrillary tangles and senile plaques in the brain.

Conclusion

SNRNP48 is a protein that has been shown to be involved in the formation of neurofibrillary tangles and senile plaques in Alzheimer's disease. Its potential as a drug target or biomarker for this disease is further confirmed by several studies, including those that have shown its levels are reduced in individuals with Alzheimer's disease and that it is associated with increased neurofibrillary tangles and senile plaques in the brain. Further research is needed to confirm its role and to develop it as a diagnostic or therapeutic target for Alzheimer's disease.

Protein Name: Small Nuclear Ribonucleoprotein U11/U12 Subunit 48

Functions: Likely involved in U12-type 5' splice site recognition

The "SNRNP48 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNRNP48 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets